ETON PHARMACEUTICALS INC

ETON PHARMACEUTICALS INC Share · US29772L1089 · ETON (XNAS) — real-time quotes, company data, dividends, fundamentals, and AI-powered portfolio analysis on MoneyPeak

Overview
AI-Powered Analysis
Fundamental Analysis
Find out what the numbers really say — before the market does
Analyze now
News Sentiment
Are today's headlines a buy signal or a red flag?
Analyze now
Buy / Hold / Sell
Should you Buy, Hold, or Sell? Get the AI verdict now.
Analyze now
Risk Assessment
Uncover hidden risks before they hit your portfolio.
Analyze now
Fair Value
Is this stock cheap, fairly priced, or overvalued?
Analyze now
Latest AI Analyses of ETON PHARMACEUTICALS INC
Analyst Grade Summary
gauge-img
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell
0
6
0
0
0
No Price
01.05.2026 20:00
Current Prices from ETON PHARMACEUTICALS INC
ExchangeTickerCurrencyLast TradePriceDaily Change
XNAS: NASDAQ
NASDAQ
ETON
USD
01.05.2026 20:00
28,90 USD
4,78 USD
+19,82 %
IEXG: IEX
IEX
ETON
USD
01.05.2026 19:59
28,91 USD
4,79 USD
+19,86 %
Share Float & Liquidity
Free Float 84,95 %
Shares Float 23,18 M
Shares Outstanding 27,28 M
Company Profile for ETON PHARMACEUTICALS INC Share
Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing pharmaceutical products for rare diseases. The company offers Biorphen, a phenylephrine injection for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; and Rezipres, a ready-to-use formulation of a molecule that is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia. It also offers Alkindi Sprinkle, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; EPRONTIA, a liquid formulation of topiramate; and Alaway Preservative Free, a preservative-free ophthalmic product to treat allergic conjunctivitis. In addition, the company develops Zonisamide Oral Suspension for the treatment of partial on-set seizures; Lamotrigine for Oral Suspension for the treatment of partial on-set seizures; cysteine injection; dehydrated alcohol injection; and Zeneo hydrocortisone autoinjector. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.

Company Data

Name ETON PHARMACEUTICALS INC
Company Eton Pharmaceuticals, Inc.
Symbol ETON
Website https://www.etonpharma.com
Primary Exchange XNAS NASDAQ
ISIN US29772L1089
Asset Class Share
Sector Healthcare
Industry Biotechnology
CEO Sean E. Brynjelsen
Market Capitalization 658 Mio
Country United States of America
Currency USD
Employees 0,0 T
Address 21925 West Field Parkway, 60010-7208 Deer Park
IPO Date 2018-11-13

Ticker Symbols

Name Symbol
NASDAQ ETON
More Shares
Investors who hold ETON PHARMACEUTICALS INC also have the following shares in their portfolio:
AON CORP 19/22
AON CORP 19/22 Bond
CANSTAR RES INC
CANSTAR RES INC Share